Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15058849 | 0.90 | KMT2A (0.55) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL30042128 | 0.86 | KMT2A (0.59) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL113270 | 0.86 | KMT2A (0.59) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29362617 | 0.86 | KMT2A (0.59) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL44676 | 0.86 | KMT2A (0.58) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL7767154 | 0.85 | FABP5 (0.54) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29598813 | 0.85 | FABP5 (0.54) | KMT2AFABP5FABP7CA1CA2 | |
| Hydrochloric Acid SCHEMBL1234617 | 0.85 | KMT2A (0.57) | KMT2AFABP5FABP7CA1CA2 | |
| Ammonia Solution, Strong SCHEMBL16430851 | 0.85 | KMT2A (0.57) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL7720044 | 0.84 | KMT2A (0.58) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-12415171-B2 | Regulation of DNA synthesis by nucleotides linked to protecting groups | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | disclosed |
| EP-4547671-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12252739-B2 | Selectively controllable cleavable linkers | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250075259-A1 | SELECTIVELY CONTROLLABLE CLEAVABLE LINKERS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-03-06 | — | — | US | disclosed |
| WO-2025024822-A2 | PROCESSES FOR MAKING ARYL COMPOUNDS THAT MODULATE IKZF2 | Plexium, Inc. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-119255997-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2025-01-03 | — | — | CN | disclosed |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | disclosed |
| EP-4413149-A1 | REGULATION OF DNA SYNTHESIS BY NUCLEOTIDES LINKED TO PROTECTING GROUPS | Microsoft Technology Licensing, LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-10131658-B2 | Anti-alphavbeta1 integrin compounds and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180312500-A9 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-11-01 | — | — | US | disclosed |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | UNIV CALIFORNIA (US) | 2016-12-29 | — | — | US | disclosed |
| CN-105154498-A | Semi-recombinant preparation of GLP-1 analogues | NOVO NORDISK AS | 2015-12-16 | — | — | CN | disclosed |
| CN-101910193-A | Semi-recombinant preparation method of GLP-1 analogue | NOVO NORDISK AS | 2010-12-08 | — | — | CN | disclosed |
| US-5854410-A | Oligonucleoside cleavage compounds and therapies | GENTA INCORPORATED (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0542887-B1 | PSORALEN CONJUGATED METHYLPHOSPHONATE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS FOR CHRONIC MYELOGENOUS LEUKEMIA | GENTA INC (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0542887-A1 | PSORALEN CONJUGATED METHYLPHOSPHONATE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS FOR CHRONIC MYELOGENOUS LEUKEMIA | GENTA INCORPORATED (US) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992002641-A1 | PSORALEN CONJUGATED METHYLPHOSPHONATE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS FOR CHRONIC MYELOGENOUS LEUKEMIA | GENTA INCORPORATED (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002532-A1 | IMPROVED NON-NUCLEOTIDE-BASED LINKER REAGENTS FOR OLIGOMERS | GENTA INCORPORATED (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | KMT2A 1391/4885FABP5 1942/4885FABP7 2594/4885 |
| US-20250075259-A1 | SELECTIVELY CONTROLLABLE CLEAVABLE LINKERS | DNPEP, ADAM8, ADAM10 | KMT2A 1657/4885FABP5 4474/4885FABP7 3302/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | KMT2A 4279/4885FABP5 1780/4885FABP7 920/4885 |
| US-20180312500-A9 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | ITGB1, ITGAV, ITGA1 | KMT2A 3854/4885FABP5 2562/4885FABP7 4048/4885 |
| US-12252739-B2 | Selectively controllable cleavable linkers | DNPEP, ADAM8, ADAM10 | KMT2A 1657/4885FABP5 4474/4885FABP7 3302/4885 |
| US-10131658-B2 | Anti-alphavbeta1 integrin compounds and methods | ITGB1, ITGAV, ITGA1 | KMT2A 3854/4885FABP5 2562/4885FABP7 4048/4885 |
| US-20160376266-A1 | ANTI-ALPHAVBETA1 INTEGRIN COMPOUNDS AND METHODS | ITGB1, ITGAV, ITGA1 | KMT2A 3854/4885FABP5 2562/4885FABP7 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.